BRIEF-Repros Announces Negative Opinion From The EMA For Enclomiphene [Reuters]
Royalty Pharma plc - Class A Ordinary Shares (RPRX)
US:NASDAQ Investor Relations:
ir.reprosrx.com/investor-relations
Company Research
Source: Reuters
BRIEF-Repros Announces Negative Opinion From The EMA For Enclomiphene | Reuters Reuters Staff 1 Min Read Jan 26 (Reuters) - Repros Therapeutics Inc: * REPROS ANNOUNCES NEGATIVE OPINION FROM THE EMA FOR ENCLOMIPHENE * CHMP HAS FORMALLY ISSUED A NEGATIVE OPINION FOR CENTRALIZED MAA FOR ENCLOMIPHENE FOR TREATMENT OF SECONDARY HYPOGONADISM Source text for Eikon: Further company coverage: All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays. Š 2018 Reuters. All Rights Reserved. BRIEF-Repros Announces Negative Opinion From The EMA For Enclomiphene Jan 26 (Reuters) - Repros Therapeutics Inc: * REPROS ANNOUNCES NEGATIVE OPINION FROM THE EMA FOR ENCLOMIPHENE * CHMP HAS FORMALLY ISSUED A NEGATIVE OPINION FOR CENTRALIZED MAA FOR ENCLOMIPHENE FOR TREATMENT OF SECONDARY HYPOGONADISM Source text for Eikon: Further company coverage:
Show less
Read more
Impact Snapshot
Event Time:
RPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RPRX alerts
High impacting Royalty Pharma plc - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
RPRX
News
- Lightning Round: M&T Bank is a buy, I like the banks, says Jim Cramer [CNBC]CNBC
- 3 High-Yield Dividend Growth Stocks to Buy in December and Hold for a Decade or Longer [Yahoo! Finance]Yahoo! Finance
- How Royalty Pharma, Open Text And VICI Properties Can Put Cash In Your Pocket [Yahoo! Finance]Yahoo! Finance
- Royalty Pharma to Present at Upcoming Investor ConferencesGlobeNewswire
- Why Royalty Pharma (RPRX) is the Cheapest Stock to Buy on Robinhood? [Yahoo! Finance]Yahoo! Finance
RPRX
Sec Filings
- 11/8/24 - Form SC
- 11/6/24 - Form 10-Q
- 11/6/24 - Form 8-K
- RPRX's page on the SEC website